Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) has been assigned a consensus recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $42.33.
Several research firms recently issued reports on SION. JonesTrading cut shares of Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 10th. Lifesci Capital cut Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Wall Street Zen cut Sionna Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Finally, Citizens Jmp lowered shares of Sionna Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, August 10th.
Check Out Our Latest Stock Analysis on SION
Insider Activity
In related news, Director Ra Capital Management, L.P. sold 3,448,811 shares of Sionna Therapeutics stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $6.33, for a total transaction of $21,830,973.63. Following the transaction, the director owned 3,448,812 shares of the company's stock, valued at $21,830,979.96. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.10% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. Chicago Partners Investment Group LLC acquired a new stake in Sionna Therapeutics in the third quarter worth $39,000. State of Alaska Department of Revenue purchased a new position in shares of Sionna Therapeutics during the 3rd quarter worth approximately $105,000. Engineers Gate Manager LP purchased a new position in Sionna Therapeutics in the second quarter worth about $686,000. AXQ Capital LP purchased a new stake in Sionna Therapeutics in the second quarter worth approximately $202,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Sionna Therapeutics by 9,056.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,622 shares of the company's stock worth $467,000 after purchasing an additional 10,506 shares during the period.
Sionna Therapeutics Stock Performance
SION stock opened at $3.87 on Monday. The business has a 50-day simple moving average of $5.45 and a two-hundred day simple moving average of $30.10. Sionna Therapeutics has a 52-week low of $3.55 and a 52-week high of $54.97. The company has a market capitalization of $174.96 million, a P/E ratio of -1.78 and a beta of 1.23.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.02). As a group, sell-side analysts forecast that Sionna Therapeutics will post -2.54 earnings per share for the current fiscal year.
Sionna Therapeutics Company Profile
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. The company is working to address the underlying cause of CF by developing small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Sionna's research centers on the nucleotide-binding domain 1 (NBD1) of CFTR, which plays an important role in the protein's structure and activity.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.